Abbott Laboratories (NYSE:ABT) Shares Bought by America First Investment Advisors LLC

America First Investment Advisors LLC increased its position in Abbott Laboratories (NYSE:ABT) by 1.8% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 186,850 shares of the healthcare product maker’s stock after acquiring an additional 3,219 shares during the period. Abbott Laboratories makes up 4.8% of America First Investment Advisors LLC’s portfolio, making the stock its 12th biggest position. America First Investment Advisors LLC’s holdings in Abbott Laboratories were worth $21,303,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Ameriprise Financial Inc. boosted its position in Abbott Laboratories by 5.0% during the 2nd quarter. Ameriprise Financial Inc. now owns 10,675,827 shares of the healthcare product maker’s stock worth $1,103,997,000 after acquiring an additional 508,524 shares during the period. Dimensional Fund Advisors LP lifted its holdings in Abbott Laboratories by 27.4% in the second quarter. Dimensional Fund Advisors LP now owns 7,428,752 shares of the healthcare product maker’s stock worth $771,940,000 after purchasing an additional 1,596,835 shares during the period. Diamond Hill Capital Management Inc. grew its position in Abbott Laboratories by 8.5% in the 3rd quarter. Diamond Hill Capital Management Inc. now owns 6,683,586 shares of the healthcare product maker’s stock valued at $761,996,000 after buying an additional 524,683 shares in the last quarter. Swiss National Bank increased its stake in Abbott Laboratories by 0.5% during the 3rd quarter. Swiss National Bank now owns 5,163,580 shares of the healthcare product maker’s stock valued at $588,700,000 after buying an additional 26,000 shares during the period. Finally, The Manufacturers Life Insurance Company raised its position in shares of Abbott Laboratories by 13.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 4,654,712 shares of the healthcare product maker’s stock worth $483,673,000 after buying an additional 563,506 shares in the last quarter. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories Trading Down 1.0 %

Abbott Laboratories stock opened at $115.93 on Thursday. The company has a 50 day moving average price of $115.54 and a 200 day moving average price of $109.74. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.14 and a current ratio of 1.60. Abbott Laboratories has a 52 week low of $99.71 and a 52 week high of $121.64. The firm has a market capitalization of $201.08 billion, a price-to-earnings ratio of 35.24, a P/E/G ratio of 2.73 and a beta of 0.72.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Wednesday, October 16th. The healthcare product maker reported $1.21 earnings per share for the quarter, beating the consensus estimate of $1.20 by $0.01. Abbott Laboratories had a return on equity of 20.18% and a net margin of 13.99%. The firm had revenue of $10.64 billion for the quarter, compared to analyst estimates of $10.55 billion. During the same period in the previous year, the firm earned $1.14 earnings per share. Abbott Laboratories’s quarterly revenue was up 4.9% on a year-over-year basis. Research analysts forecast that Abbott Laboratories will post 4.67 EPS for the current year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, November 15th. Investors of record on Tuesday, October 15th were given a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a yield of 1.90%. The ex-dividend date was Tuesday, October 15th. Abbott Laboratories’s payout ratio is presently 66.87%.

Insider Buying and Selling at Abbott Laboratories

In other news, CEO Robert B. Ford sold 141,679 shares of the company’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $116.41, for a total value of $16,492,852.39. Following the transaction, the chief executive officer now directly owns 220,059 shares of the company’s stock, valued at approximately $25,617,068.19. This represents a 39.17 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.47% of the company’s stock.

Analyst Upgrades and Downgrades

ABT has been the topic of a number of research analyst reports. Jefferies Financial Group raised their price objective on shares of Abbott Laboratories from $120.00 to $125.00 and gave the company a “hold” rating in a research note on Thursday, October 17th. Piper Sandler lifted their price target on Abbott Laboratories from $131.00 to $133.00 and gave the company an “overweight” rating in a research report on Thursday, October 17th. Oppenheimer assumed coverage on Abbott Laboratories in a research note on Tuesday, October 8th. They issued an “outperform” rating and a $130.00 price objective on the stock. Raymond James reaffirmed a “buy” rating and set a $129.00 target price (up previously from $122.00) on shares of Abbott Laboratories in a research note on Monday, October 14th. Finally, Sanford C. Bernstein boosted their price target on shares of Abbott Laboratories from $133.00 to $138.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. Four research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $130.07.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.